• Thorat T, Lin PJ, Neumann PJ. The State of Cost-Utility Analyses in Asia: A Systematic Review. Value Health Regional Issues. 2015 May 7–13. [Abstract]
  • Chambers JD, Thorat T, Pyo J, Neumann PJ. The lag from FDA approval to published cost-utility evidence. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 12:1-4. [PubMed]
  • Saret CJ, Winn A, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015 Feb 5. [PubMed]
  • Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. Value Health. 2015 Mar;18(2):308-314. [PubMed]
  • Neumann PJ, Thorat T, Shi J, Saret CJ, Cohen JT. The changing face of the cost-utility literature, 1990-2012. Value Health. 2015 Mar;18(2):271-7. [PubMed] [Complete Journal List]


  • Cohen JT. FDA's proposed ban on trans fats: How do the costs and benefits stack up? Clin Ther. 2014 Mar 1;36(3):322-7. [PubMed]
  • Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014 Aug 28;371(9):796-7. [PubMed]
  • Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs. Health Aff (Millwood). 2014 Oct;33(10):1751-60. [PubMed]


  • Tetteh E, Morris S. Systematic review of drug administration costs and implications for biopharmaceutical manufacturing. Appl Health Econ Health Policy. 2013 Oct;11(5):445-56. [PubMed]
  • Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflamm Bowel Dis. 2013 Nov;19(12):2673-94.  [PubMed]
  • Richards D. Only limited evidence available for the effectiveness and cost effectiveness of dental auxiliaries. Evid Based Dent. 2013;14(2):38-9. [PubMed]
  • Olchanski N, Cohen JT, Neumann PJ. A role for research: an observation on preventive services for women. Am J Prev Med. 2013 Jan;44(1 Suppl 1):S12-5. [PubMed


  • Saab S, Choi Y, Rahal H, Li K, Tong M. Trends in Viral Hepatitis Cost-Effectiveness Studies. Am J Manag Care. 2012;18(12):790-798. [Link]
  • Chokshi DA and Farley TA.  The Cost-Effectiveness of Environmental Approaches to Disease Prevention.  NEJM. 2012(367)2950297. [PubMed]
  • Otero HJ, Fang CH, Sekar M, Ward RJ, Neumann PJ. Accuracy, Risk and the Intrinsic Value of Diagnostic Imaging: A Review of the Cost-utility Literature. Acad Radiol. 2012 Feb 18.  [PubMed]
  • Wilson AW, Neumann PJ. The cost-effectiveness of biopharmaceuticals: A look at the evidence. [PubMed]
  • Simoens S. What is the value for money of medicines? A registry study. J Clin Pharm Ther. 2012 Apr;37(2):182-6. [PubMed]
  • Finnell SM, Carroll AE, Downs SM. Application of classic utilities to published pediatric cost-utility studies. Acad Pediatr. 2012 May;12(3):219-28. [PubMed]
  • Miller G, Cohen JT, Roehrig C. Cost-effectiveness of cardiovascular disease spending. J Am Coll Cardiol. 2012 Nov 13;60(20):2123-4. [PubMed]
  • Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367:595-605. [PubMed]


  • Greenberg D, Neumann PJ. Is it cost-effective? It depends on who you ask. In Rosen B, Israeli A, Shortell S (ed). Improving Health and Healthcare. Who is Responsible? Who is Accountable? The Israel National Institute for Health Policy Research, 2011.  
  • Kamae MS, Kamae I, Cohen JT, Neumann PJ. Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. Journal of Medical Economics 2011. Feb 18;14(2)187-93.  [PubMed]*
  • Greenberg, D and Neumann, PJ. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? Expert Rev. Pharmacoeconomics Outcomes Res. 11(1), 113-119 [PubMed]
  • Braithwaite RS and Mentor SM.  Identifying Favorable-Value Cardiovascular Health Services.  American Journal of Managed Care.  2011;17(6):431-438.  [PubMed]
  • Fang C, Otero HJ, Greenberg D, Neumann PJ. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health. 2011 Dec;14(8):1010-8. [PubMed]


  • Otero HJ, Rybicki FJ, Greenberg D, Mitsouras D, Mendoza JA, Neumann PJ. Cost-Effective Diagnostic Cardiovascular Imaging: When Does It Provide Good Value for the Money? International Journal of Cardiovascular Imaging 2010. Aug;26(6):605-12. [PubMed]
  • Chambers JD, Neumann PJ, Buxton MJ.  Does Medicare Have an Implicit Cost-Effectiveness Threshold? Medical Decision Making 2010 Jul-Aug;30(4):E14-27. [PubMed] *
  • Meckley LM, Greenberg D, Cohen JT, Neumann PJ. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. Medical Decision Making 2010 May-Jun;30(3):314-9. [PubMed]
  • Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. “Low-value” services in value-based insurance design. American Journal of Managed Care 2010;16(4):280-286. [PubMed]
  • Greenberg D, Rosen AB, Wacht O, Palmer JA, Neumann PJ. A bibliometric review of cost-effectiveness analysis in the economic and medical literature, 1976-2007. Medical Decision Making. 2010 May-Jun;30(3):320-7. [PubMed]
  • Greenberg D, Earle CC, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility studies in oncology. Journal of the National Cancer Institute 2010;102(2):82-88.[PubMed]


  • Nelson AL, Cohen JT, Greenberg D, Kent DM. Much cheaper, almost as good: Decrementally cost-effective medical innovation. Annals of Internal Medicine 2009 Nov;151(9):662-667. [PubMed]
  • Rosen AB, Spaulding A, Greenberg D, Palmer JA, Neumann PJ. Patient adherence: A blind spot in cost-effectiveness analysis? Am J Manag Care. 2009 Sep;15(9):626-32. [PubMed]
  • Neumann PJ. Costing and perspective in published cost-effectiveness analyses. Medical Care. 2009; 47(7s1):s28-s32. [PubMed]
  • Neumann PJ, Fang CH, Cohen JT, 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics. 2009; 27 (10):861-872. [PubMed]


  • Cohen JT, Neumann PJ, Weinstein MC. Does prevention care save money? Health economics and the presidential candidates. New England Journal of Medicine. 2008 Feb(7);358:661-663. [PubMed]
  • Neumann PJ, Jacobson PD, Palmer JA. Measuring the value of public health systems: The disconnect between health economists and public health practioners. American Journal of Public Health. 2008 Dec;98(12):2173-2180. [PubMed]
  • Otero HJ, Rybicki FJ, Greenberg D, Neumann PJ. 20 years of cost-effectiveness analysis in medical imaging: Are we improving?. Radiology. 2008 Dec;249(3):917-925. [PubMed]


  • Brauer C, Neumann PJ, Rosen AB. Trends in Cost Effectiveness Analysis in Orthopedic Surgery. Clin Ortho Rel Res. 2007 Apr;457:42-8. [PubMed]
  • Ladapo JA, Neumann PJ, Keren R, Prosser LA. Valuing Children's Health: A Comparison of Cost-Utility Analyses for Adult and Paediatric Health Interventions in the US. Review Article. Pharmacoeconomics. 2007; 25(10):817-828. [PubMed]
  • Neumann PJ, Kamae M, Palmer JA. Medicare’s national coverage decisions for technologies, 1999-2007. Health Affairs. 2008;27(6):1620–1631 [Pubmed] *


  • Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ. Is Everything in Health Care Cost-Effective? Bias in Published Cost-Effectiveness Studies. British Medical Journal 2006;332:699-703. [PubMed]
  • Brauer C, Greenberg D, Rosen AB, Neumann PJ. Trends in the Use of Health Utilities in Published Cost-Utility Analyses. Value in Health. 2006;9(4):213-18. [PubMed]
  • Hahn RW, Kosec K, Neumann PJ, Wallsten S. What Affects the Quality of Economic Analysis for Life-Saving Investments? AEI-Brookings. Risk Analysis. 2006;26(3):641-55. [PubMed]
  • Neumann PJ, Lin PJ, Greenberg D, Berger M, Teutsch S, Mansley E, Rosen AB, Weinstein MC. Do drug formulary policies reflect evidence of value? American Journal of Managed Care. 2006 12(1):30-6. [PubMed]
  • Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ. When is Critical Care Medicine Cost-Effective? A Systematic Review of the Cost-Effectiveness Literature. Critical Care Medicine. 2006;34(11):2738-47. [PubMed]


  • Brauer CA, Olchanski NV, Rosen AB, Neumann PJ. Cost-utility analyses in orthopedic surgery. Journal of Bone and Joint Surgery (Am) 2005;87(6):1253-9. [PubMed]
  • Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford University Press. 2005. [Amazon]
  • Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value in Health. 2005;8(1):3-9. [PubMed]
  • Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, Weinstein MC. Can We Better Prioritize Resources for Cost-Utility Research? Medical Decision Making. 2005;25(4):429-36. [PubMed]
  • Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. New England Journal of Medicine. 2005;353:1516-22. [PubMed]
  • Neumann PJ, Divi N, Beinfeld MT, Levine BS, Keenan PS, Halpern EF, Gazelle GS. Medicare's national coverage decisions, 1999-2003: quality of evidence and review times. Health Aff (Millwood). 2005;24(1):243-54 [Pubmed] *
  • Rosen AB, Greenberg D, Stone PW, Olchanski NV, Neumann PJ. Quality of Abstracts of Papers Reporting Original Cost-Effectiveness Analyses. Medical Decision Making. 2005;25(4):424-28. [PubMed]
  • Stone PW, Schackman B, Neukermans CP, Olchanski N, Greenberg D, Rosen A, Neumann PJ. A Synthesis of Cost-Utility Analysis Literature in Infectious Disease. Lancet Infectious Diseases. 2005; 383-91. [PubMed]


  • Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When Does Quality-Adjusting Life-Years Matter in Cost-Effectiveness Analysis? Health Economics. 2004;13(5):429-36. [PubMed]
  • Greenberg D, Rosen AB, Olchanski NV, Stone PW, Nadai J, Neumann PJ. Delays in Publications of Cost-Utility Analyses Conducted Alongside Clinical Trials: Registry Analysis. British Medical Journal. 2004; 328:1536-1537. [PubMed]
  • Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann PJ. Cost Utility Analysis Studies of Depression Management: A Systematic Review. Am J Psychiatry. 2004; 161(12):2155-62. [PubMed]
  • Schackman BR, Gold HT, Stone PW, Neumann PJ. How Often do Sensitivity Analyses for Economic Parameters Change Cost-Utility Analysis Conclusions? PharmacoEconomics 2004;22(5):293-300. [PubMed]


  • Winkelmayer WC, Cohen D, Berger M, Neumann PJ. Comparing Cost-Utility Analyses in Cardiovascular Medicine. Cardiovascular Health Care Economics, Weintraub WS, editor. Totowa, NJ: Humana Press, 2003: 329-356. [Book]


  • Neumann PJ, Levine BS. Do HEDIS Measures Reflect Cost-Effective Practices? American Journal of Preventive Medicine. 2002; 23(4):276-289. [PubMed]


  • Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An Off-the-Shelf Help List: A Comprehensive Catalog of Utility Scores from Published Cost-Utility Analyses. Med Decis Making 2001; 21:288-94. [PubMed]


  • Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A Comprehensive League Table of Cost-Utility Ratios and a Sub-Table of "Panel-Worthy" Studies. Medical Decision Making. 2000; 20:451-67. [PubMed]
  • Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, and Neumann PJ. Systematic Overview of Cost-Utility Assessments in Oncology. Journal of Clinical Oncology. 2000; 18:3302-17. [PubMed]
  • Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are Pharmaceuticals Cost-Effective? A Review of the Evidence. Health Affairs. 2000; 19(2):92-109. [PubMed]
  • Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The Quality of Reporting in Published Cost-Utility Analyses, 1976-1997. Annals of Internal Medicine. 2000; 132(12):964-72. [PubMed]
  • Stone PW, Teutsch S, Chapman RH, Bell C, Neumann PJ. Cost-Utility Analyses of Clinical Prevention Services 1976-1997. American Journal of Preventive Medicine. 2000; 19:15-23. [PubMed]
  • Stone PW, Chapman RC, Sandberg EA, Liljas B, Neumann PJ. Measuring Costs in Cost-Utility Analyses: Variations in the literature. International Journal of Technology Assessment in Health Care. 2000; 16(1):111-124. [PubMed]
    *  Publication using National Coverage Determination Database



  • Chambers JC, Weiner DE, Bliss SK, Neumann PJ. What can we learn from the US expanded end-stage renal disease bundle? Health Policy. 2013; (110):164-171. [PubMed]
  • Lerner D, Rodday AM, Cohen JT, Rogers WH. A Systematic Review of the Evidence Concerning the Economic Impact of Employee-Focused Health Promotion and Wellness Programs. J Occup Environ Med. 2013 Jan 2. [PubMed
  • Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers and Dementia. 2013; (9):58–62. [PubMed]
  • Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders. Alzheimer’s & Dementia 9 (2013) 30–38. [PubMed]
  • Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The Validity of Dependence as a Health Outcome Measure in Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2013 Mar 19. [PubMed]


  • Cangelosi MJ, Bliss SK, Chang H, Dubois RW, Lerner D, Neumann PJ, Westrich K, Cohen JT.  Imputing productivity gains from clinical trials. Journal of Occupational and Environmental Medicine.  In Press.
  • Cohen JT, Marino RJ, Sacco P, Terrin N.  Association between the Functional Independence Measure following spinal cord injury and long term outcomes.  Spinal Cord.  In Press.
  • Leslie LK, Cohen JT, Newburger JW, Alexander ME, Wong JB, Sherwin ED, Rodday AM, Parsons SK, Triedman JK.  Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents.  Circulation.  In Press.
  • Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Affairs 2012; 31(4):700-708.
  • Neumann PJ, What we talk about when we talk about health care costs. New England Journal of Medicine. 2012 Feb;366(7):585-86. 
  • Neumann, PJ, Cohen, JT, Hammitt, JK, Concannon, TW, Auerbach, HR, Fang, CH, Kent, DM. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics 2012. 21:238-251.
  • Rodday AM, Triedman JK, Alexander ME, Cohen JT, Ip S, Newburger JW, Parsons SK, Trikalinos TA, Wong JB, Leslie LK. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic Children: A meta-analysis. Pediatrics. 2012 Apr; 129(4):1-12.  
  • Thorat T, Cangelosi M, Neumann PJ. Skills of the trade: The Tufts cost-effectiveness analysis registry. Journal of Benefit-Cost Analysis. 2012 Feb;3(1):1-7.
  • Wilson AW, Neumann PJ, The cost-effectiveness of biopharmaceuticals: A look at the evidence. mAbs. Mar;4(2):281-288.


  • Buxton, MJ, Chambers, JD. What values do the public want their health care systems to use in evaluating technologies? European Journal of Health Economics. Published online May 15, 2011. PMID: 21573933
  • Cangelosi, MJ, Auerbach, HR, Cohen, JT. A clinical and economic evaluation of enteral nutrition. Current Medical Research Opinion. 2011 Feb;27(2):413-22. Epub 2010 Dec 30. PMID: 21192760
  • Chambers J, Neumann PJ. Listening to Provenge — what a costly cancer treatment says about Medicare policy on new technology. New England Journal of Medicine. 2011 May 5;364(18):1687-9. PMID: 21470004
  • Gazelle GS, Kessler L, Lee DW, McGinn T, Menzin J, Neumann PJ, van Amerongen D, White LA. The Working Group on Comparative Effectiveness Research for Imaging. A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research. Radiology 2011 Dec;261(3):692-698. PMID: 22095993
  • Maciejewski ML, Wang VW, Grabowski DC, Lin PJ. Early evidence on the quality of care provided by special needs plans. Medical Care 2011;49(10):891-896. PMID: 21572358
  • Neumann PJ, Chambers J, Simon F, Meckley L. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs. 2011 Dec; 30(4): 2329-2337. PMID:22147861
  • Neumann, PJ, Cohen, JT, Hammitt, JK, Concannon, TW, Auerbach, HR, Fang, CH, Kent, DM. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics 2011. Published online Dec. 28, 2010. PMID: 21190163
  • Neumann PJ. What’s next for QALYs. Journal of the American Medical Association 2011 May; 305(17):1806-1807. PMID: 21540426
  • Neumann PJ, Lin PJ, Hughes TE. FDAMA Section 114: Current Uses and Opportunities for Comparative Effectiveness Research. Pharmacoeconomics 2011 July; 29(8):687-692. PMID: 21540426
  • Yang Z, Zhang K, Lin PJ, Clevenger CK, Atherly A. A longitudinal analysis of the lifetime cost of dementia. Health Services Research. 2011 Dec 15. PMID: 22171532


  • Berry SR, Bell CM, Ubel PA et al. Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated with New Cancer Drugs. J Clin Oncol 2010 PubMed: 20697077
  •  Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010; 96:179-190.
  • Chambers JD, Neumann PJ. US healthcare reform: implications for health economics and outcomes research. Expert Review Pharmacoeconomic Outcomes Research 2010; 10(3):215-216. PubMed: 20545583
  • Cohen JT. Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. Expert Review Pharmacoeconomic Outcomes Research 2010; 10(5):595-603. PubMed
  • Fillit H, Cummings J, Neumann PJ, McLaughin T. Salvatore P, Leibman C. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer’s disease. The Journal of Nutrition Health & Aging 2010; 14(8):640-647.c
  •  Garrison LP, Jr., Neumann PJ, Radensky P, Walcoff SD. A flexible approach to evidentiary standards for comparative effectiveness research. Health Affairs (Millwood) 2010; 29(10):1812-1817.
  • Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. How long and how well: oncologists’ attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Medical Decision Making. 2010. Published online, November 24, 2010.
  • Lin PJ, Maciejewski ML, Paul JE, Biddle AK. Risk adjustment for Medicare beneficiaries with Alzheimer’s disease and related dementias. American Journal of Managed Care 2010;16(3):191-198. PubMed: 20225914
  • McLaughin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan MJ, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Yaakov. Dependence as a unifying contruct in defining Alzheimer’s disease severity. Alzheimer’s and Dimentia 2010; 6(1):482-493.
  • Meckley LM, Neumann PJ. Personalized medicine: Factors influencing reimbursement. Health Policy 2010;94:91-100. PubMed: 19815307
  • Neumann PJ, Drummond MF, Jönsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Are key principles for improved health technology assessment supported and used by HTA organizations? International Journal of Technology Assessment in Health Care 2010 Jan;21(1):71-78. PubMed: 20059783
  • Luce BR, Drummond M, Jonsson B et al. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010; 88(2):256-276 PubMed: 20579285
  • Neumann PJ, Weinstein M.C. Legislating against use of cost-effectiveness information. New England Journal of Medecine 2010; 363(16):1495-1497. PubMed
  • Rothberg MB, Cohen JT, Lindenauer P, Maselli J, Auerbach AD. Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality. Health Affairs (Millwood) 2010; 29(8):1523-1531.
  • Shaya FT, Yan X, Lin PJ, Simoni-Wastia L, Bron M, Baran R, Donner T. US Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes. Journal of Clinical Hypertension 2010;12(10):826–832.


  • Brixner, DI, Holtorf, AP, Neumann, PJ, Malone, DC, Watkins, JB Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm. 2009;15:(3)275-283. PubMed: 19326959
  • Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? Am J Transplant 2009; 9(1):23-30. PubMed: 19067660
  • Neumann PJ. Are mAbs different? A commentary on Cohen and Wilson. MaBs. 2009;1(1):29-30.http://www.landesbioscience.com/
  • Neumann PJ. American exceptionalism and American health care: Implications for the U.S. debate on cost-effectiveness analysis. Office of Health Economics Briefing. 2009;47.http://www.ohe.org/
  • Neumann PJ. Whatever happened to FDAMA Section 114? A look back after 10 years. Value Health 2009; 12(2):189-190. PubMed: 18657100
  • Neumann PJ. Lessons for health technology assessment: It is not only about the evidence. Value in Health 2009; 12(s2):s45-s48. PubMed: 19523184


  • Cohen JT, Neumann PJ. Using decision analysis to better evaluate pediatric clinical guidelines. Health Affairs. 2008 Sep-Oct;27(5):1467-75. PubMed: 18780939
  • Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. New England Journal of Medicine. 2008 Feb(7);358:661-663. PubMed: 18272889
  • Otero HJ, Rybicki FJ, Greenberg D, Neumann PJ. 20 years of cost-effectiveness analysis in medical imaging: Are we improving?. Radiology. 2008 Dec;249(3):917-925. PubMed: 19011188
  • Neumann PJ, Jacobson PD, Palmer JA. Measuring the value of public health systems: The disconnect between health economists and public health practitioners. American Journal of Public Health. 2008 Dec;98(12):2173-2180. PubMed: 18923123 
  • Neumann PJ, Kamae MS, Palmer JA. Medicare’s national coverage decisions for technologies, 1999-2007. Health Affairs. 2008 Nov:27(6):1620-1631. PubMed: 18997221
  • Palmer JA, Timm AR, Neumann PJ. Drug Company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999. Journal of Managed Care Pharmacy. 2008;14(8):749-55. PubMed: 18983204
  • Jacobson PD, Neumann PJ. A framework to measure the value of public health services. Health Services Research. PubMed: 19686250.
  • Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer’s case definitions using Medicare claims and survey data. Alzheimers and Dementia. PubMed: 20434960
  • Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med. PubMed: 19954941
  • Neumann PJ. Costing and perspective in published cost-effectiveness analyses. Medical Care. 2009; 47(7s1):s28-s32. PubMed: 19536023
  • Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics. PubMed: 19803540

Fall 2012 Newsletter

CEVR Fall 2012 Newsletter

Spring 2012 Newsletter

CEVR Sping 2012 Newsletter 

Fall 2011 Newsletter

CEVR Fall 2011 Newsletter 

Spring 2011 Newsletter

CEVR Spring 2011 Newsletter

Spring 2010 Newsletter

CEVR Spring 2010 Newsletter

Fall 2009 Newsletter

CEVR Fall 2009 Newsletter